

PredicineATLAS™

CLIA Validated 600-Gene cfDNA NGS Assay


Pan-cancer NGS assay for comprehensive variant profiling
compatible with liquid biopsy and solid tumor sample types

600

Key cancer genes interrogated

80+


Clinically relevant oncology
biomarkers



Methods and Reporting

- Identify key genomic aberrations including, single nucleotide variants (SNVs), insertions and/or deletions (Indels), copy number variations (CNVs), DNA rearrangements, tumor mutational burden (TMB), microsatellite instability (MSI), homologous recombination deficiency (HRD), and tumor fraction (TF)
- Comprehensive tumor profiling integrated with PredicineSCORE Low-pass whole genome sequencing; no additional samples input required
- Covers genes of interest across drug development pipelines from targeted therapies to immunotherapies

Workflow






Performance Specifications

Feature	Plasma	Tissue
Detection Sensitivity	SNVs/ Indels: 0.25% AF, reportable range $\geq$ 0.05%; DNA Rearrangements: 0.25% AF, reportable range $\geq$ 0.05%; Copy number Gains: 2.23-2.37 copies, reportable range $\geq$ 2.18 copies Microsatellite Instability (MSI): 1% TF Tumor Mutational Burden (TMB): 0.7% TF	SNVs/ Indels: 2.5% AF, reportable range $\geq$ 1%; DNA Rearrangements: 3.5% AF, reportable range $\geq$ 1%; Copy number Gains: 4.5-8.5 copies, reportable range $\geq$ 2.35 copies
Turnaround Time (TAT)	6 days	10 days
Specimen Type and Requirement (CLIA)	20 mL blood	$\geq$ 1mm ³ tissue (5-10 FFPE slides)
Specimen Type and Requirement (RUO)	2-5 mL plasma 4-10 mL blood	$\geq$ 1mm ³ tissue (5-10 FFPE slides)
Target Sequence Coverage	20,000x	2,000x
Genomic and Assay Features	SNVs, Indels, CNVs, DNA Rearrangements, TMB, MSI, HRD, Tumor Fraction	
Sequencing	Illumina NGS	
Analytical Validation	CLIA/CAP-accredited workflows	

Note: Some features are only included in the RUO version. Additional information available upon request.

Case study: ctDNA molecular response correlates with clinical outcomes



Zang, et al. Journal of Pathology, 2023

Cancer cell fraction (CCF, evaluated by PredicineATLAS) predicts response to immunotherapy in bladder cancer.